Peg-IFNα monotherapy is a treatment recommended by the Chinese international clinical practice treatment guidelines to help more CHB patients achieve a sustained off-treatment virological response and prevent unfavorable events such as cirrhosis and HCC [39]. This evidence concerns the gene IFNA1 and Cirrhosis.